PULM stock forecast
Our latest prediction for Pulmatrix, Inc.'s stock price was made on the April 3, 2018 when the stock price was at 0.49$.
In the short term (2weeks), PULM's stock price should outperform the market by 7.45%. During that period the price should oscillate between -11.86% and +31.59%.
In the medium term (3months), PULM's stock price should outperform the market by 15.16%. During that period the price should oscillate between -23.11% and +87.55%.Get email alerts
About Pulmatrix, Inc.
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.63$ per share.
The book value per share is 0.35$
Three months stock forecastApril 3, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|